{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T07:43:41Z","timestamp":1776930221295,"version":"3.51.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T00:00:00Z","timestamp":1529625600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009010","name":"Novartis Pharmaceuticals UK Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12886-018-0824-0","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T22:30:12Z","timestamp":1529620212000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept"],"prefix":"10.1186","volume":"18","author":[{"given":"Pallavi","family":"Tyagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zain","family":"Juma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Keen","family":"Hor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil W.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreea","family":"Ionean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,22]]},"reference":[{"key":"824_CR1","doi-asserted-by":"crossref","unstructured":"Zayit-Soudry, Shiri et al. Retinal pigment epithelial detachment Surv Ophthalmol, 2007;52(3):227\u201343.","DOI":"10.1016\/j.survophthal.2007.02.008"},{"key":"824_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1442-9071.1998.tb01335.x","volume":"26","author":"M Gross-Jendroska","year":"1998","unstructured":"Gross-Jendroska M, Flaxel CJ, Schwartz SD, et al. Treatment of pigment epithelial detachments due to age-related macular degeneration with intra-ocular C3F8 injection. Aust N Z J Ophthalmol. 1998;26:311\u20137.","journal-title":"Aust N Z J Ophthalmol"},{"key":"824_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/archopht.122.4.453","volume":"122","author":"R Axer-Seigel","year":"2004","unstructured":"Axer-Seigel R, Ehrlich R, Rosenblatt I, et al. Photodynamic therapy for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. Arch Ophthalmol. 2004;122:453\u20139.","journal-title":"Arch Ophthalmol"},{"key":"824_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1177\/112067210501500318","volume":"15","author":"M Nicolo","year":"2005","unstructured":"Nicolo M, Ghiglione D, Lai S, Calabria G. Intravitreal triamcinolone in the treatment of serous pigment epithelial detachment and occult choroidal neovascularization secondary to age-related macular degeneration. Eur J Ophthalmol. 2005;15:415\u20139.","journal-title":"Eur J Ophthalmol"},{"key":"824_CR5","unstructured":"Ranibizumab and pegaptanib for the treatment of age-related - NICE.\n                    https:\/\/www.nice.org.uk\/guidance\/ta155\n                    \n                  .27.Aug.2008."},{"key":"824_CR6","unstructured":"Aflibercept solution for injection for treating wet age-related macular degeneration - NICE \n                    https:\/\/www.nice.org.uk\/guidance\/ta294\n                    \n                  ."},{"key":"824_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171\u201385.","journal-title":"Angiogenesis"},{"key":"824_CR8","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537\u201348.","journal-title":"Ophthalmology"},{"key":"824_CR9","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/bjo.2007.134874","volume":"92","author":"MW Stewart","year":"2008","unstructured":"Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF trap. Br J Ophthalmol. 2008;92:667\u20138.","journal-title":"Br J Ophthalmol"},{"key":"824_CR10","doi-asserted-by":"publisher","unstructured":"Adrian A, Parikh VS, Singh RP, et al. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration. Br J Ophthalmol. 2016 Dec 2; \n                    https:\/\/doi.org\/10.1136\/bjophthalmol-2016-309434\n                    \n                  .","DOI":"10.1136\/bjophthalmol-2016-309434"},{"key":"824_CR11","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1097\/IAE.0b013e31821987a4","volume":"31","author":"WR Freeman","year":"2011","unstructured":"Freeman WR, Kozak I, Yuson RM, et al. Prognostic implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization. Retina. 2011;31:1812\u20138.","journal-title":"Retina"},{"key":"824_CR12","doi-asserted-by":"publisher","unstructured":"Giansanti F, Bacherini D, Giacomelli G et al. Intravitreal anti-VEGF therapy for vascularized pigment epithelium detachment in age-related macular degeneration. Eur J Ophthalmol 2014 May-Jun;24(3):402\u2013408. doi: \n                    https:\/\/doi.org\/10.5301\/ejo.5000388\n                    \n                  . Epub 2013 Nov 12.","DOI":"10.5301\/ejo.5000388"},{"key":"824_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000337251","volume":"228","author":"T Baba","year":"2012","unstructured":"Baba T, Kitahashi M, Kubota-Taniai M, et al. Two-year course of subfoveal pigment epithelial detachment in eyes with age related macular degeneration and visual acuity better than 20\/40. Ophthalmologica. 2012;228:102\u20139.","journal-title":"Ophthalmologica"},{"issue":"4","key":"824_CR14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00417-016-3564-y","volume":"255","author":"O Chevreaud","year":"2017","unstructured":"Chevreaud O, Oubraham H, Cohen SY, Jung C, Blanco-Garavito R, Gherdaoui F, Souied EH. Ranibizumab for vascularized pigment epithelial detachment: 1-year anatomic and functional results. Graefes Arch Clin Exp Ophthalmol. 2017 Apr 1;255(4):743\u201351.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"824_CR15","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/eye.2011.115","volume":"25","author":"S Arora","year":"2011","unstructured":"Arora S, McKibbin M. One-year outcome after intravitreal ranibizumab for large, serous pigment epithelial detachment secondary to age-related macular degeneration. Eye. 2011;25(8):1034\u20138. \n                    https:\/\/doi.org\/10.1038\/eye.2011.115\n                    \n                  .","journal-title":"Eye"},{"key":"824_CR16","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1097\/IAE.0b013e3182755793","volume":"33","author":"M Inoue","year":"2013","unstructured":"Inoue M, Arakawa A, Yamane S, Kadonosono K. Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy. Retina. 2013;33:990\u20137.","journal-title":"Retina"},{"key":"824_CR17","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2147\/DDDT.S46610","volume":"7","author":"GD Panos","year":"2013","unstructured":"Panos GD, Gatzioufas Z, Petropoulos IK, et al. Effect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degeneration. Drug Des Devel Ther. 2013;7:565\u20139.","journal-title":"Drug Des Devel Ther"},{"key":"824_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/eye.2014.233","volume":"29","author":"CK Chan","year":"2015","unstructured":"Chan CK, Abraham P, Sarraf D, et al. Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration. Eye (Lond). 2015;29:80\u20137.","journal-title":"Eye (Lond)"},{"issue":"10","key":"824_CR19","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/j.ophtha.2016.07.007","volume":"23","author":"D Sarraf","year":"2016","unstructured":"Sarraf D, London NJ, Khurana RN, et al. Ranibizumab treatment for pigment epithelial detachment secondary to Neovascular age-related macular degeneration: post hoc analysis of the HARBOR study. Ophthalmology. 2016 Oct;23(10):2213\u201324. \n                    https:\/\/doi.org\/10.1016\/j.ophtha.2016.07.007.","journal-title":"Ophthalmology"},{"key":"824_CR20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ajo.2016.03.039","volume":"166","author":"HJ Cho","year":"2016","unstructured":"Cho HJ, Kim KM, Kim HS, et al. Response of pigment epithelial detachment to anti-vascular endothelial growth factor treatment in age-related macular degeneration. Am J Ophthalmol. 2016 Jun;166:112\u20139. \n                    https:\/\/doi.org\/10.1016\/j.ajo.2016.03.039\n                    \n                  .","journal-title":"Am J Ophthalmol"},{"key":"824_CR21","doi-asserted-by":"publisher","unstructured":"Dirani A, Ambresin A, Marchionno L et al. Factors influencing the treatment response of pigment epithelium detachment in age-related macular degeneration. Am J Ophthalmol 2015 Oct;160(4):732\u20138.e2. doi: \n                    https:\/\/doi.org\/10.1016\/j.ajo.2015.06.025\n                    \n                  . Epub 2015 Jul 2.","DOI":"10.1016\/j.ajo.2015.06.025"},{"issue":"7","key":"824_CR22","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1097\/IAE.0000000000001342","volume":"37","author":"K Balaskas","year":"2017","unstructured":"Balaskas K, Karampelas M, Horani M, et al. Quantitative analysis of pigment epithelial detachment response to different anti-vascular endothelial growth factor agents in wet age-related macular degeneration. Retina. 2017 Jul;37(7):1297\u2013304.","journal-title":"Retina"},{"key":"824_CR23","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1097\/IAE.0b013e31828e8551","volume":"33","author":"N Kumar","year":"2013","unstructured":"Kumar N, Marsiglia M, Mrejen S, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina. 2013;33:1605\u201312.","journal-title":"Retina"},{"key":"824_CR24","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/eye.2013.31","volume":"27","author":"KH Patel","year":"2013","unstructured":"Patel KH, Chow CC, Rathod R, et al. Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye (Lond). 2013;27:663\u20137.","journal-title":"Eye (Lond)"},{"key":"824_CR25","doi-asserted-by":"publisher","first-page":"273754","DOI":"10.1155\/2014\/273754","volume":"2014","author":"M Gharbiya","year":"2014","unstructured":"Gharbiya M, Iannetti L, Parisi F, et al. Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Biomed Res Int. 2014;2014:273754.","journal-title":"Biomed Res Int"},{"key":"824_CR26","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/eye.2014.101","volume":"28","author":"DS Grewal","year":"2014","unstructured":"Grewal DS, Gill MK, Sarezky D, et al. Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Eye (Lond). 2014;28:895\u20139.","journal-title":"Eye (Lond)"},{"issue":"3","key":"824_CR27","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/IAE.0000000000000749","volume":"36","author":"L He","year":"2016","unstructured":"He L, Silva RA, Moshfeghi DM, Blumenkranz MS, Leng T. Aflibercept for the treatment of retinal pigment epithelial detachments. Retina. 2016 Mar;36(3):492\u20138.","journal-title":"Retina"},{"issue":"5","key":"824_CR28","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/IAE.0000000000000409","volume":"35","author":"GK Broadhead","year":"2015","unstructured":"Broadhead GK, Hong T, Zhu M, Li H, Schlub TE, Wijeyakumar W, Chang AA. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration. Retina. 2015 May;35(5):975\u201381.","journal-title":"Retina"},{"issue":"5","key":"824_CR29","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1097\/IAE.0000000000000813","volume":"36","author":"S de Massougnes","year":"2016","unstructured":"de Massougnes S, Dirani A, Ambresin A, et al. Pigment epithelial detachment response to aflibercept in neovascular age-related macular degeneration refractory to ranibizumab: time course and drug effects. Retina. 2016 May;36(5):881\u20138.","journal-title":"Retina"},{"key":"824_CR30","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/bjophthalmol-2013-303155","volume":"97","author":"OS Punjabi","year":"2013","unstructured":"Punjabi OS, Huang J, Rodriguez L, et al. Imaging characteristics of neovascular pigment epithelial detachments and their response to anti-vascular endothelial growth factor therapy. Br J Ophthalmol. 2013;97:1024\u201331.","journal-title":"Br J Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-018-0824-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-018-0824-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-018-0824-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T06:57:26Z","timestamp":1569308246000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-018-0824-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,22]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["824"],"URL":"https:\/\/doi.org\/10.1186\/s12886-018-0824-0","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,22]]},"assertion":[{"value":"28 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.This is a retrospective audit from data collected from electronic medical record. No patient identifiable data used.As per the UK Health Departments\u2019 Governance Arrangements for Research Ethics Committees (GAfREC) guidance, \u201cResearch limited to secondary use of information previously collected in the course of normal care (without an intention to use it for research at the time of collection) is generally excluded from REC review, provided that the patients or service users are not identifiable to the research team in carrying out the research. This exception also applies to research undertaken by staff within a care team using information previously collected in the course of care for their own patients or clients, provided that data is anonymised or pseudonymised in conducting the research.\u201dGAfREC is available at\n            \n            .","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The study was carried out independently however PT received travel grant from BAYER, UK to attend international meetings and AI and CS have received travel grants and speaker fees from Bayer and Novartis and acted as consultants for BAYER, UK.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"148"}}